Product
Leuprorelin
Aliases
Leuplin SR for Injection Kit 11.25 mg, Leuprorelin acetate, Leuprorelin Acetate
6 clinical trials
6 indications
Indication
Spinal and Bulbar Muscular AtrophyIndication
Breast NeoplasmsIndication
Uterine FibroidsIndication
Cesarean SectionIndication
Breast CancerIndication
Prostate CancerClinical trial
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.Status: Completed, Estimated PCD: 2020-07-14
Clinical trial
A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With MenorrhagiaStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar DefectStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Multi-institutional Study to Increase Breast Conserving Surgery (BCS) Rate With Personalized Neoadjuvant Strategy in ER Positive and HER2 Negative Breast Cancer Patients for Whom BCS is Not FeasibleStatus: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapyStatus: Recruiting, Estimated PCD: 2024-12-01